Nivolumab (nivo) in combination with radiotherapy (RT) ± temozolomide (TMZ): Updated safety results from CheckMate 143 in pts with methylated or unmethylated newly diagnosed glioblastoma (GBM)

被引：0
|
作者：
Lim, M. [1 ]
Omuro, A. [2 ]
Vlahovic, G. [3 ]
Reardon, D. A. [4 ,5 ]
Sahebjam, S. [6 ]
Cloughesy, T. [7 ]
Baehring, J. [8 ]
Butowski, N. [9 ]
Potter, V. [10 ]
Zwirtes, R. [10 ]
Paliwal, P. [10 ]
Carleton, M. [10 ]
Sampson, J. [3 ]
Brandes, A. A. [11 ]
机构：
[1] Johns Hopkins Univ, Sch Med, Metastat Brain Tumor Ctr, Baltimore, MD USA
[2] Mem Sloan Kettering Canc Ctr, Neurol, 1275 York Ave, New York, NY 10021 USA
[3] Duke Univ, Med Ctr, Preston Robert Tisch Brain Tumor Ctr Duke, Durham, NC USA
[4] Dana Farber Canc Inst, Ctr Neurooncol, Boston, MA 02115 USA
[5] Harvard Univ, Sch Med, Boston, MA USA
[6] Univ S Florida, H Lee Moffitt Canc Ctr, Oncol, Tampa, FL 33682 USA
[7] Univ Calif Los Angeles, Neurol Oncol, Los Angeles, CA USA
[8] Yale Sch Med, Neurol, New Haven, CT USA
[9] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA
[10] Bristol Myers Squibb Co, Oncol, Princeton, NJ USA
[11] AUSL IRCCS Inst Neurol Sci, Neurol, Bologna, Italy
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3250
引用
收藏
页数：1
相关论文
共 50 条
  • [1] NIVOLUMAB IN COMBINATION WITH RADIOTHERAPY WITH OR WITHOUT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA: UPDATED RESULTS FROM CHECKMATE 143
    Omuro, A.
    Vlahovic, G.
    Baehring, J.
    Butowski, N.
    Reardon, D.
    Cloughesy, T.
    Sahebjam, S.
    Lim, M.
    Zwirtes, R.
    Sampson, J.
    NEURO-ONCOLOGY, 2017, 19 : 13 - 13
  • [2] Safety and activity of nivolumab (nivo) monotherapy and nivo in combination with ipilimumab (ipi) in recurrent glioblastoma (GBM): Updated results from checkmate-143.
    Reardon, David A.
    Sampson, John H.
    Sahebjam, Solmaz
    Lim, Michael
    Baehring, Joachim M.
    Vlahovic, Gordana
    Cloughesy, Timothy Francis
    Strauss, Lewis C.
    Latek, Robert Raymond
    Paliwal, Prashni
    Harbison, Christopher T.
    Voloschin, Alfredo Daniel
    Omuro, Antonio Marcilio Padula
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] NIVOLUMAB COMBINED WITH RADIOTHERAPY WITH OR WITHOUT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA: RESULTS FROM PHASE 1 SAFETY COHORTS IN CHECKMATE 143
    Omuro, Antonio
    Vlahovic, Gordana
    Baehring, Joachim
    Butowski, Nicholas Arthur
    Reardon, David A.
    Cloughesy, Timothy
    Sahebjam, Solmaz
    Lim, Michael
    Strauss, Lewis
    Latek, Robert
    Zwirtes, Ricardo
    Paliwal, Prashni
    Harbison, Chris
    Sampson, John
    NEURO-ONCOLOGY, 2016, 18 : 21 - 21
  • [4] Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143
    Omuro, Antonio
    Reardon, David A.
    Sampson, John H.
    Baehring, Joachim
    Sahebjam, Solmaz
    Cloughesy, Timothy F.
    Chalamandaris, Alexandros-Georgios
    Potter, Von
    Butowski, Nicholas
    Lim, Michael
    NEURO-ONCOLOGY ADVANCES, 2022, 4 (01)
  • [5] A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498.
    Sampson, John H.
    Omuro, Antonio Marcilio Padula
    Preusser, Matthias
    Lim, Michael
    Butowski, Nicholas A.
    Cloughesy, Timothy Francis
    Strauss, Lewis C.
    Latek, Robert Raymond
    Paliwal, Prashni
    Weller, Michael
    Reardon, David A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] SAFETY RESULTS FROM AVAglio, A PHASE III RANDOMIZED STUDY OF BEVACIZUMAB (BEV) PLUS STANDARD COMBINATION TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
    Saran, Frank
    Chinot, Olivier L.
    Henriksson, Roger
    Mason, Warren
    Wick, Wolfgang
    Nishikawa, Ryo
    Dahr, Sunita
    Hilton, Magalie
    Garcia, Josep
    Cloughesy, Timothy
    NEURO-ONCOLOGY, 2013, 15 : 127 - 128
  • [7] Combination of temozolomide (TMZ) and radiotherapy (RT) versus radiotherapy (RT) alone in newly diagnosed glioblastoma multiforme (GBM): A randomized phase II study
    Athanassiou, H
    Synodinou, M
    Maragoudakis, E
    Paraskevaidis, M
    Verigos, C
    Misailidou, D
    Antonadou, D
    Sarris, G
    Beroukas, K
    Karageorgis, P
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (01): : S162 - S163
  • [8] NIVOLUMAB AND TEMOZOLOMIDE (TMZ) VS TMZ ALONE IN NEWLY DIAGNOSED ELDERLY PATIENTS (PTS) WITH GLIOBLASTOMA (GBM) (NUTMEG): TRIAL IN PROGRESS
    Khasraw, M.
    McDonald, K.
    Yip, S.
    Verhaak, R. G.
    Heimberger, A. B.
    Hall, M.
    Barnes, E.
    Hovey, E.
    Ellingson, B. M.
    Lwin, Z.
    NEURO-ONCOLOGY, 2018, 20 : 236 - 236
  • [9] PSEUDOPROGRESSION (PSPR) AFTER CONCURRENT RADIOTHERAPY (RT) AND TEMOZOLOMIDE (TMZ) FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM)
    Clarke, Jennifer
    Abrey, Lauren
    Karimi, Sasan
    Lassman, Andrew
    NEURO-ONCOLOGY, 2008, 10 (05) : 893 - 893
  • [10] Pseudoprogression (PsPr) after concurrent radiotherapy (RT) and temozolomide (TMZ) for newly diagnosed glioblastoma multiforme (GBM)
    Clarke, J. L.
    Abrey, L. E.
    Karimi, S.
    Lassman, A. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345